CytoDyn announced that the FDA has lifted the clinical hold on leronlimab. The Company is now free to proceed with its proposed HIV clinical trial exploring leronlimab and its effects on chronic inflammation. CytoDyn’s CEO, Dr. Jacob Lalezari, stated, “We are excited that the clinical hold on leronlimab has been lifted by the FDA. CytoDyn is grateful for the FDA’s guidance on our protocol and we are excited to open a new chapter in the development of leronlimab as a therapy that provides clinical benefit by modulating chronic inflammation.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on CYDY:
- CytoDyn Announces Submission of Clinical Protocol to FDA and Initiation of Pre-Clinical Study in Glioblastoma
- CytoDyn submits revised HIV clinical trial protocol to FDA
- CytoDyn Releases Regulatory FD Disclosure Information
- CytoDyn Announces Executive Leadership Changes and Appointments
- CytoDyn Appoints Jacob Lalezari M.D. as CEO, Mitchell Cohen as Interim CFO
